Designation and Research OECI standards v.4.0



Mef Nilbert, MD, PhD, professor Vice chair, Accreditation and Designation Board

Athens, 11th June 2025

ACCREDITATION AND DESIGNATION PROGRAMME



Data collected on research capacities, metrics and standards

Research metrics

Research standards

Research capacities

Designation scheme

- Scientific publications, IF levels
- Clinical interventional trials, fraction of patients recruited

Qualitative questionnaire

 E.g. research strategy, SAB, dissemination, talent development, processes for scientific misconduct, IP, innovation

Quantative questionnaire

 E.g. funding, research groups, output, clinical trials, biobank





Focus on research throughout the revision process



Oct 2023

2024

Feb 2025

- Compare all available standards world-wide
- Compile ideas from auditors and centers
- Workshop in A&D board

- Analysis of current centers' performance
- Research standards working group

 Online conference on research standards with ~70 scientific directors

Complete research cycle
Clarification; examples and glossary
Overlapping standards
Research >15% of standards
Higher requirements for CCC status
Standard on patient involvement
Distinction of institutional authors

Standards Revision
 Conference involving
 professional societies:
 ESMO, ESTRO, ESSO, ECL,
 DKH





Research standards

- Around 50 substandards (18%) on research
- Core standards include e.g. scientific report, protected time, dissemination program, innovation, ethics committee/IRB and clinical trials database
- A few new standards, e.g. research director requirements, public and private involvement in research, policies for data sharing, quality assurance program for clinical research
- 10+ standards significantly revised standards





CORE essential standards in research

Two CORE essential research standards

- Regularly updated <u>research strategic plan</u> covering at least 3 years
- There is a dedicated cancer trials unit

Four core essential research standards for CCCs

- Research groups and output covering <u>fundamental</u>, <u>translational</u> and <u>clinical</u> research
- The cancer centre organises access to <u>shared technological platforms</u> for research activities
- An external <u>SAB</u> meets at regular intervals and advises the cancer centre on its cancer research strategy, organisation, infrastructure and overall performance
- There are mechanisms in place to provide clinical staff <u>protected time</u> for clinical and/or translational research





Updated designation scheme

ACCREDITATION AND DESIGNATION PROGRAMME

CC vs CCC level requirements remains roughly the same, but the level of open interventional clinical trials cut from 75 to 60

	Criteria OECI Cancer Centre	Criteria OECI Comprehensive Cancer Centre
Presence of the three treatment facilities surgery oncology, radiotherapy and medical oncology, and research and education?	Qualitative / quantitative assessment through accreditation	Qualitative / quantitative assessment through accreditation
between brackets the amount as indicated in the e-	> 25 million euro*	> 80 million eur *
between brackets the amount as indicated in the e-		> 8 million euro"
Number of FTE physicians dedicated to cancer (2.3.1)	> 30	> 80
Number of newly treated cancer patients per year (2.1.1.2)	> 1500	> 2500

	Criteria OECI Cancer Centre	Criteria OECI Comprehensive Cancer Centre
Number of FTE dedicated to cancer research (8.6.1)		> 50
Number of international peer reviewed scientific publications (3-year annual average) (8.4.2)	>35	> 125
Number of international peer reviewed scientific publications with an impact factor (IF) over 10 (8.4.2)		> 17
Number of international peer reviewed scientific publications with 1st, 2nd, last author (or corresponding author) - (3-year annual average) (8.4.2)		> 50
Number of trials active - currently open for patient accrual (new definition - Subtotal for Designation (A)) (8.5.1.2)	>20	> 60
Do these open trials include Phase I trials? (8.5.1.2)		Yes
The total number of patients recruited to prospective interventional clinical trials in the index year as ratio of patients newly treated in the centre (8.5.1.8)		>1:10





Thank you for your attention!



